Develops oral drug candidates for patients with neurologic, gastrointestinal, inflammatory and autoimmune diseases.
10-K for FY2025, filed Feb 26, 2026
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
10-Q for Q3 FY2026, filed Nov 13, 2026
−$42.3MView ↗
8-K, filed Aug 11, 2026
On August 7, 2026, the Company entered into a Separation Agreement (the “Separation Agreement”) with Dr. Vitt, pursuant to which Dr. Vitt’s…View ↗
Loading...